227 related articles for article (PubMed ID: 21779443)
1. The genomics of lung adenocarcinoma: opportunities for targeted therapies.
Greulich H
Genes Cancer; 2010 Dec; 1(12):1200-10. PubMed ID: 21779443
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive genomic characterization of squamous cell lung cancers.
Cancer Genome Atlas Research Network
Nature; 2012 Sep; 489(7417):519-25. PubMed ID: 22960745
[TBL] [Abstract][Full Text] [Related]
3. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.
Imielinski M; Berger AH; Hammerman PS; Hernandez B; Pugh TJ; Hodis E; Cho J; Suh J; Capelletti M; Sivachenko A; Sougnez C; Auclair D; Lawrence MS; Stojanov P; Cibulskis K; Choi K; de Waal L; Sharifnia T; Brooks A; Greulich H; Banerji S; Zander T; Seidel D; Leenders F; Ansén S; Ludwig C; Engel-Riedel W; Stoelben E; Wolf J; Goparju C; Thompson K; Winckler W; Kwiatkowski D; Johnson BE; Jänne PA; Miller VA; Pao W; Travis WD; Pass HI; Gabriel SB; Lander ES; Thomas RK; Garraway LA; Getz G; Meyerson M
Cell; 2012 Sep; 150(6):1107-20. PubMed ID: 22980975
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive molecular profiling of lung adenocarcinoma.
Cancer Genome Atlas Research Network
Nature; 2014 Jul; 511(7511):543-50. PubMed ID: 25079552
[TBL] [Abstract][Full Text] [Related]
5. Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers.
Freire Boullosa L; Van Loenhout J; Flieswasser T; Hermans C; Merlin C; Lau HW; Marcq E; Verschuuren M; De Vos WH; Lardon F; Smits ELJ; Deben C
Antioxidants (Basel); 2023 Mar; 12(3):. PubMed ID: 36978917
[TBL] [Abstract][Full Text] [Related]
6. Targeted molecular profiling of solid tumours-Indian tertiary cancer centre experience.
Gurav M; Epari S; Gogte P; Pai T; Deshpande G; Karnik N; Shetty O; Desai S
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7413-7425. PubMed ID: 36935431
[TBL] [Abstract][Full Text] [Related]
7. Induction and preliminary characterization of neoplastic pulmonary nodules in a transgenic pig model.
Ghosn M; Elsakka AS; Petre EN; Cheleuitte-Nieves C; Tammela T; Monette S; Ziv E; Schachtschneider KM; Srimathveeravalli G; Yarmohammadi H; Edward Boas F; Solomon SB
Lung Cancer; 2023 Apr; 178():157-165. PubMed ID: 36868176
[TBL] [Abstract][Full Text] [Related]
8. Novel ATM Gene c.5644 C > T (p.Arg1882*) Variant Detected in a Patient with Pancreatic Adenocarcinoma and Two Primary Non-Small Cell Lung Adenocarcinomas: A Case Report.
Aljamal AA; Elajami MK; Mansour EH; Bahmad HF; Medina AM; Cusnir M
Diseases; 2022 Dec; 10(4):. PubMed ID: 36547201
[TBL] [Abstract][Full Text] [Related]
9. Advanced non-small cell lung cancer treated with palliative systemic therapy complicated by calvarial metastasis: a case report.
Patel S; Zaita B; Singh A; Tatachar V; Dias S; Fattakhov E; Kaur G
Transl Cancer Res; 2022 Sep; 11(9):3357-3362. PubMed ID: 36237247
[TBL] [Abstract][Full Text] [Related]
10. Anaplastic lymphoma kinase rearrangements in patients with non-small cell lung cancer in Jordan.
Maraqa B; Al-Ashhab M; Sughayer MA
J Int Med Res; 2022 Jun; 50(6):3000605221104181. PubMed ID: 35689392
[TBL] [Abstract][Full Text] [Related]
11. Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma.
Fahrmann JF; Tanaka I; Irajizad E; Mao X; Dennison JB; Murage E; Casabar J; Mayo J; Peng Q; Celiktas M; Vykoukal JV; Park S; Taguchi A; Delgado O; Tripathi SC; Katayama H; Soto LMS; Rodriguez-Canales J; Behrens C; Wistuba I; Hanash S; Ostrin EJ
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626147
[TBL] [Abstract][Full Text] [Related]
12. Folate-Decorated Cross-Linked Cytochrome c Nanoparticles for Active Targeting of Non-Small Cell Lung Carcinoma (NSCLC).
Dominguez-Martinez I; Joaquin-Ovalle F; Ferrer-Acosta Y; Griebenow KH
Pharmaceutics; 2022 Feb; 14(3):. PubMed ID: 35335867
[TBL] [Abstract][Full Text] [Related]
13. Quantifying the contribution of transcription factor activity, mutations and microRNAs to CD274 expression in cancer patients.
Bruns IB; Beltman JB
Sci Rep; 2022 Mar; 12(1):4374. PubMed ID: 35289334
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic KRAS promotes growth of lung cancer cells expressing SLC3A2-NRG1 fusion via ADAM17-mediated shedding of NRG1.
Shin DH; Kim SH; Choi M; Bae YK; Han C; Choi BK; Kim SS; Han JY
Oncogene; 2022 Jan; 41(2):280-292. PubMed ID: 34743207
[TBL] [Abstract][Full Text] [Related]
15. Gene Expression Profiling as a Potential Tool for Precision Oncology in Non-Small Cell Lung Cancer.
Hijazo-Pechero S; Alay A; Marín R; Vilariño N; Muñoz-Pinedo C; Villanueva A; Santamaría D; Nadal E; Solé X
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638221
[TBL] [Abstract][Full Text] [Related]
16. A methylation-based nomogram for predicting survival in patients with lung adenocarcinoma.
Wang X; Zhou B; Xia Y; Zuo J; Liu Y; Bi X; Luo X; Zhang C
BMC Cancer; 2021 Jul; 21(1):801. PubMed ID: 34247575
[TBL] [Abstract][Full Text] [Related]
17. DNA repair pathways and their roles in drug resistance for lung adenocarcinoma.
Kara A; Özgür A; Nalbantoğlu S; Karadağ A
Mol Biol Rep; 2021 Apr; 48(4):3813-3825. PubMed ID: 33856604
[TBL] [Abstract][Full Text] [Related]
18. Molecular subtypes based on DNA promoter methylation predict prognosis in lung adenocarcinoma patients.
Shi S; Xu M; Xi Y
Aging (Albany NY); 2020 Nov; 12(23):23917-23930. PubMed ID: 33237038
[TBL] [Abstract][Full Text] [Related]
19. Targeting 14-3-3ζ Overcomes Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma via BMP2/Smad/ID1 Signaling.
Cui J; Song Y; Han X; Hu J; Chen Y; Chen X; Xu X; Xing Y; Lu H; Cai L
Front Oncol; 2020; 10():542007. PubMed ID: 33123465
[No Abstract] [Full Text] [Related]
20. Integration of gene profile to explore the hub genes of lung adenocarcinoma: A quasi-experimental study.
Hua P; Zhang Y; Jin C; Zhang G; Wang B
Medicine (Baltimore); 2020 Oct; 99(43):e22727. PubMed ID: 33120770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
